Anticancer drugs with chemotherapeutic interactions with thymoquinone in osteosarcoma cells

Basit Öğe Kaydı
dc.authorid0000-0003-2221-4731en_US
dc.authorid0000-0002-2604-5333
dc.contributor.authorSarman, Hakan
dc.contributor.authorBayram, Recep
dc.contributor.authorBenek, Bedri Selim
dc.date.accessioned2021-06-23T19:43:40Z
dc.date.available2021-06-23T19:43:40Z
dc.date.issued2016
dc.departmentBAİBÜ, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümüen_US
dc.departmentBAİBÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü
dc.departmentBAİBÜ, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü
dc.description.abstractOBJECTIVE: Osteosarcoma (OS) is the most common primary malignant tumor of the bone. Treatment options include surgery, chemotherapy, and radiotherapy. Following surgery, multi-agent chemotherapy drugs are effective but are associated with significant side effects and toxicity. Thymoquinone (TMQ) is a pharmacological component of black cumin that has multiple anti-tumorigenic effects. The goal of this study was to determine the effect of TMQ in combination with chemotherapy drugs on the growth inhibition of osteosarcoma and the potential clinical utility of TMQ in the treatment of OS. MATERIALS AND METHODS: We evaluated the effects on the MG63 OS cell line when TMQ, 5-fluorouracil, and oxaliplatin combinations were applied that MG63 OS cell line viability was measured with the cell proliferation and apoptosis assay according to dose and time-dependent effects. RESULTS: Application of 10 mu M TMQ combined with 5FU and OXA at a low concentration of 1 mu M that was discovered an ineffective dose of the used drugs as anticancer decreased cell viability and increased apoptosis in cells at a significant rate at 48 and 72 h. CONCLUSIONS: TMQ has potential benefits in preventing the onset and progression of chemotherapy drug-induced toxicity and side effects, and may reduce resistance to chemotherapy drugs. We consider that TMQ may be a potential therapeutic drug for OS and/or other cancers.en_US
dc.identifier.endpage1270en_US
dc.identifier.issn1128-3602
dc.identifier.issue7en_US
dc.identifier.pmid27097945en_US
dc.identifier.scopus2-s2.0-85017185621en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1263en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12491/8826
dc.identifier.urihttps://www.webofscience.com/wos/woscc/full-record/WOS:000376904300010
dc.identifier.volume20en_US
dc.identifier.wosWOS:000376904300010en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorSarman, Hakan
dc.institutionauthorBayram, Recep
dc.institutionauthorBenek, Bedri Selim
dc.language.isoenen_US
dc.publisherVerduci Publisheren_US
dc.relation.ispartofEuropean Review For Medical And Pharmacological Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectOsteosarcomaen_US
dc.subjectChemotherapyen_US
dc.subjectNigella Sativaen_US
dc.subjectThymoquinoneen_US
dc.subject5-Fluorouracilen_US
dc.subjectOxaliplatinen_US
dc.subjectLow Dose Effectiveen_US
dc.subjectLow Toxicityen_US
dc.titleAnticancer drugs with chemotherapeutic interactions with thymoquinone in osteosarcoma cellsen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
1263-1270.pdf
Boyut:
2.4 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Cerrahi Tıp Bilimleri Bölümü Koleksiyonu
Dahili Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Temel Tıp Bilimleri Bölümü Koleksiyonu